Diagnostic assistance, quantification, characterization, image reconstruction: medical artificial intelligence at your fingertips for radiology.
Back to AI solutions

icobrain dm CE

Supporting differential diagnosis and monitoring of atrophy in dementia

Discover

icobrain dm is designed to support the early detection of markers of dementias, comparing whole brain and ventricular volumes to age- and sex-matched healthy controls. icobrain dm can also used to assist radiologists and neurologists with the differential diagnosis of the particular type of dementia a patient may have, by providing individual volumes of the cortical lobes and hippocampi, and reporting percentiles compared to the age- and sex-matched healthy control population. Additionally, icobrain dm can help radiologists and neurologists to evaluate eligibility for amyloid-targeting treatments for Alzheimer's disease, by reporting out the total volume of FLAIR white matter hyperintensities, as well as the number of T2* GRE hypointensities.

The average time between the onset of symptoms and diagnosis is three years. Globally, 60% of dementia cases go undetected. Furthermore, 70% of primary care physicians are not up to date with the latest Alzheimer’s disease care practices. As a result, 80% of patients are diagnosed too late, by which point their disease has already progressed significantly.
icobrain dm CE

Automatic analysis of 3D T1 sequences


Enables early detection, follow-up and differential diagnosis of Alzheimer and other dementia


Quantifies and tracks cortical brain volumes and asymmetries to differentiate common dementia types (frontal, parietal, temporal, occipital, hippocampal)


Comparing volumes and volume changes to an age-and sex- matched normative reference population


40% Reduction in radiological reading time

35% increased radiological consistency

Automated standardized reports

Save time, secure your diagnosis and optimize your workflow with Incepto

Request a demo

Publications

  1. Van Hecke W, Costers L, Descamps A, Ribbens A, Nagels G, Smeets D, Sima DM. A Novel Digital Care Management Platform to Monitor Clinical and Subclinical Disease Activity in Multiple Sclerosis. Brain Sci. 2021 Sep 3;11(9):1171. doi: 10.3390/brainsci11091171. PMID: 34573193; PMCID: PMC8469941

  2. Sima DM, Wilms G, Vande Vyvere T, Van Hecke W, Smeets D. On the use of icobrain's prepopulated radiology reporting template for multiple sclerosis follow-up. ECR 2020 / C-11342

  3. Calloni, S.F., Vezzulli, P.Q., Castellano, A. et al. Combining semi-quantitative rating and automated brain volumetry in MRI evaluation of patients with probable behavioural variant of fronto-temporal dementia: an added value for clinical practise?. Neuroradiology 65, 1025–1035 (2023). https://doi.org/10.1007/s00234-023-03133-w

  4. Hanne Struyfs, Diana Maria Sima, Melissa Wittens, Annemie Ribbens, Nuno Pedrosa de Barros, Thanh Vân Phan, Maria Ines Ferraz Meyer, Lene Claes, Ellis Niemantsverdriet, Sebastiaan Engelborghs, Wim Van Hecke, Dirk Smeets. Automated MRI volumetry as a diagnostic tool for Alzheimer's disease: Validation of icobrain dm. NeuroImage: Clinical, Volume 26, 2020, 102243,
    ISSN 2213-1582, https://doi.org/10.1016/j.nicl.2020.102243.

Regulatory

icobrain dm is a report of icobrain mr and icobrain ct. icobrain mr and icobrain ct medical devices are regulated health products that bear the CE mark, Class IIa. Notified Body: SGS Belgium NV. n°1639. Manufacturer: Icometrix NV. icobrain mr and icobrain ct are diagnostic tools and shall not be used alone to recommend medical care for diagnostic purposes. Please read the instructions in the users manual carefully. Please contact contact@incepto-medical.com for more information. Last update: 2025/06/02

Contact us to know if this product is available in your country.

Publisher

icometrix was founded in 2011, in Leuven, Belgium; striving for data-driven insights and personalized patient care, supported by artificial intelligence. They offer a portfolio of AI solutions to assist healthcare with various challenges in neurological disorders such as multiple sclerosis, brain trauma, epilepsy, stroke, dementia, and Alzheimer’s disease. Today, they are internationally active and integrated into more than 100 clinical practices and supporting pharmaceutical companies in phase I-III and Real-World Evidence (RWE) studies.